



Concert Pharmaceuticals to Report Third Quarter 2019 Financial Results on November 7, 2019

October 31, 2019

LEXINGTON, Mass.--(BUSINESS WIRE)--Oct. 31, 2019-- [Concert Pharmaceuticals, Inc.](#) (NASDAQ: CNCE) today announced that it will report its third quarter 2019 financial results on Thursday, November 7, 2019, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. ET to discuss third quarter financial results and provide a business update. Individuals interested in participating in the call should dial (855) 354-1855 (U.S. and Canada) or (484) 365-2865 (International).

A live webcast of the conference call may be accessed in the [Investors](#) section of the Company's website at www.concertpharma.com. Please log on to the Concert website approximately 15 minutes prior to the scheduled webcast to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Concert's website for three months.

About Concert

[Concert Pharmaceuticals](#) is a clinical stage biopharmaceutical company focused on applying its [DCE Platform®](#) (deuterated chemical entity platform) to create novel medicines designed to treat serious diseases and address unmet patient needs. The Company's approach starts with previously studied compounds, including approved drugs, in which deuterium substitution has the potential to enhance clinical safety, tolerability or efficacy. Concert's [pipeline](#) of innovative medicines targets autoimmune diseases and central nervous systems (CNS) disorders. For more information please visit www.concertpharma.com or follow us on Twitter at [@ConcertPharma](#) or on [LinkedIn](#).

View source version on businesswire.com: <https://www.businesswire.com/news/home/20191031005042/en/>

Source: Concert Pharmaceuticals, Inc.

Justine Koenigsberg
(781) 674-5284
ir@concertpharma.com